This early Phase I interventional trial (n=10) will assess the neurophysiological effect of ketamine in patients with severe Traumatic Brain Injury (TBI).
This pilot, non-randomised single-group study will characterise the neurophysiological response to a single dose of ketamine in critically ill patients with severe TBI monitored with intracranial pressure (ICP) and brain tissue oxygenation (PbtO2).
Primary assessments include acute changes in ICP and PbtO2 and other safety/tolerability measures; enrollment is estimated at 10 participants at Parkland Memorial Hospital.
Single-dose ketamine in severe TBI with ICP and PbtO2 monitoring.
Administration per ICU protocol; route not specified in registry text.